15 news items
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
BMY
3 Jun 24
at least one prior line of therapy, and for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
BMY
31 May 24
for Breyanzi for relapsed or refractory chronic lymphocytic leukemia
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
, and has received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after
7l07ma3h1a8zfprsv89ktdtl94h muovjrzt6thi7xmtlt51zx98y1x
BMY
23 May 24
(lisocabtagene maraleucel), demonstrating consistent clinical outcomes in relapsed/refractory chronic lymphocytic
kkfkg6dko
BMY
16 May 24
that provides sustained relief from this chronic disease, allowing patients to prioritize other aspects of their daily lives. These findings further reinforce
x9gyr
BMY
15 May 24
lymphoma (LBCL) after at least one prior line of therapy and received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic
0nj9s6
BMY
10 May 24
hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning
q1r1jb0h4scohu87twuht4
BMY
26 Apr 24
(GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome
qzghvtevbot91z7cou1p2mmfdwibjzi0tijlav3csgf
BMY
25 Apr 24
of Abecma in Earlier-Line Multiple Myeloma and Breyanzi in Chronic
nrhawv02ld6cegyxvmtr3tntcg0ncn12w13iq
BMY
25 Mar 24
agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial
affsv61sfhz4pziuzyvy7pugk88nse5lbo3m7rjw1qpwo0buvrud2
BMY
15 Mar 24
receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval covers
xgq q42tb6nqnltqgwg
BMY
15 Mar 24
lps18hibr187 y8teqiuff0
BMY
14 Mar 24
chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine
- Prev
- 1
- Next